177-11-7

Basic information

• Product Name: 1,4-Dioxa-8-azaspiro[4.5]decane
• Synonyms: 4-Piperidone ethylene ketal, 98+%;4-Piperidone ethylene ketal 98%;1,4-DIOXA-8-AZASPIRO(4.5)DECANE (4-PIPERIDONE ETHYLENE KETAL);4,4-(Ethylenedioxy)piperidine;4-Piperidinone ethylene acetal;8-Aza-1,4-dioxaspiro[4.5]decane;Piperidin-4-one ethylene ketal;Piperidine-4-one ethylene acetal
• CAS NO: 177-11-7
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 143.18
• EINECS: 205-868-6
• Product Categories: Piperidine;Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks;Piperidones
• Mol File: 177-11-7.mol

Chemical Properties

• Boiling Point: 108-111 °C26 mm Hg(lit.)
• Flash Point: 179 °F
• Appearance: Clear colorless to yellow/Liquid
• Density: 1.117 g/mL at 20 °C(lit.)
• Vapor Pressure: 0.185mmHg at 25°C
• Refractive Index: n20/D 1.4819(lit.)
• Storage Temp.: Store below +30°C.
• Solubility: DCM, Ethyl Acetate, Methanol
• PKA: 10.92±0.20(Predicted)
• Water Solubility: Soluble in water (Partly miscible).
• Sensitive: Air Sensitive
• BRN: 506799
• CAS DataBase Reference: 1,4-Dioxa-8-azaspiro[4.5]decane(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Dioxa-8-azaspiro[4.5]decane(177-11-7)
• EPA Substance Registry System: 1,4-Dioxa-8-azaspiro[4.5]decane(177-11-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-24/25
• WGK Germany: 3
• F: 10-34
• Hazardous Substances Data: 177-11-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1,4-Dioxa-8-azaspiro[4.5]decane is used as a synthetic intermediate for the production of 1,4-dioxa-8-azaspiro[4,5]deca spirocyclotriphosphazenes. These compounds exhibit unique properties and have potential applications in various fields, such as materials science and pharmaceuticals.
Used in Pharmaceutical Industry:
1,4-Dioxa-8-azaspiro[4.5]decane is used as a building block for the development of novel pharmaceutical compounds. Its unique structure allows for the creation of new molecules with potential therapeutic properties, contributing to the advancement of drug discovery and development.
Used in Materials Science:
In the field of materials science, 1,4-Dioxa-8-azaspiro[4.5]decane is used as a precursor for the synthesis of advanced materials with specific properties. These materials can be utilized in various applications, such as coatings, adhesives, and polymers, due to their unique characteristics derived from the spirocycle structure.

InChI:InChI=1/C7H13NO2/c1-3-8-4-2-7(1)9-5-6-10-7/h8H,1-6H2/p+1

Upstream product

• 37943-54-7 8-benzyl-1,4-dioxa-8-azaspiro[4.5]decane 
• 32519-75-8 N-[5-(bromoacetyl)-4-methyl-1,3-thiazol-2-yl]acetamide, hydrobromide salt 
• 915702-31-7 ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate 
• 915702-34-0 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylic acid 
• 30748-47-1 5-acetyl-4-methylthiazole-2-amine 
• 39884-12-3 5-acetyl-2-(N-acetylamino)-4-methylthiazole 
• 41979-39-9 4-piperidone hydrochloride 
• 107-21-1 ethylene glycol 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 123387-51-9 tert-butyl 1,4-dioxa-8-azaspiro[4.5]decane-8-carboxylate 
• 42899-11-6 1,4-dioxa-8-azaspiro[4.5]decane hydrochloric acid 
• 1261144-91-5 8-(3,4,5,6-tetrahydropyridin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 5625-67-2 2-Ketopiperazine 
• 915702-47-5 2'-acetylamino-4'-methyl-[4,5']bithiazolyl-2-carbonyl chloride 

Downstream Products

• 69663-56-5 8-diphenylacetyl-1,4-dioxa-8-aza-spiro[4.5]decane 
• 18951-25-2 [3-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-propyl]-(4-phenylazo-5,6,7,8-tetrahydro-naphthalen-1-yl)-amine 
• 79421-40-2 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)benzaldehyde 
• 190012-08-9 1-(4-methoxybenzoyl)-4-piperidone ethylene ketal 
• 122846-59-7 3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-hydroxy-2-phenyl-propionic acid ethyl ester 
• 79421-38-8 4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzoic acid ethyl ester 
• 79421-39-9 4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzonitrile 
• 131693-15-7 N-(pentafluorobenzoyl)-4-piperidone ethylene ketal 
• 103769-38-6 2-(1,4-Dioxa-8-aza-spiro[4.5]dec-7-yl)-1-phenyl-ethanone 
• 133019-87-1 1-(4-Benzoylbenzoyl)piperidin-4-on-ethylen-acetal 
• 149633-27-2 8-[3-(4-Fluoro-phenoxy)-propyl]-1,4-dioxa-8-aza-spiro[4.5]decane 
• 139524-60-0 1-(2,4-Difluoro-phenyl)-7-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 136933-98-7 1,4-Dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid (1S,2R,5S)-2-isopropyl-5-methyl-cyclohexyl ester 
• 139524-62-2 1-(2,4-Difluoro-phenyl)-7-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 

Relevant articles and documents

NOVEL SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.

PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity

The inclusion of an azaspiroketal Mannich base in the membrane targeting antitubercular 6-methoxy-1-n-octyl-1H-indole scaffold resulted in analogs with improved selectivity and submicromolar activity against Mycobacterium tuberculosis H37Rv. The potency enhancing properties of the spiro-fused ring motif was affirmed by SAR and validated in a mouse model of tuberculosis. As expected for membrane inserting agents, the indolyl azaspiroketal Mannich bases perturbed phospholipid vesicles, permeabilized bacterial cells, and induced the mycobacterial cell envelope stress reporter promoter piniBAC. Surprisingly, their membrane disruptive effects did not appear to be associated with bacterial membrane depolarization. This profile was not uniquely associated with azaspiroketal Mannich bases but was characteristic of indolyl Mannich bases as a class. Whereas resistant mycobacteria could not be isolated for a less potent indolyl Mannich base, the more potent azaspiroketal analog displayed low spontaneous resistance mutation frequency of 10-8/CFU. This may indicate involvement of an additional envelope-related target in its mechanism of action.

High-Temperature Boc Deprotection in Flow and Its Application in Multistep Reaction Sequences

A simplified Boc deprotection using a high-temperature flow reactor is described. The system afforded the qualitative yield of a wide variety of deprotected substrates within minutes using acetonitrile as the solvent and without the use of acidic conditions or additional workups. Highly efficient, multistep reaction sequences in flow are also demonstrated wherein no extraction or isolation was required between steps.

PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein

Two novel series of spirocyclic piperidine analogs appended to a pyrazolo[1,5-a]pyridine core were designed, synthesized and evaluated for their anti-HCV activity. A series of piperidine ketals afforded dispiro 6p which showed excellent in vitro anti-HCV activities (EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, respectively). A series of piperidine oxazolidinones afforded 27c which showed EC50's of 10.9 nM and 6.1 nM against 1a and 1b replicons, respectively. Both compounds 6p and 27c bound directly to non-structural NS4B protein in vitro (IC50's = 10.2 and 30.4 nM, respectively) and exhibited reduced potency in replicons containing resistance mutations encoding changes in the NS4B protein.

PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

C-2 arylation of piperidines through directed transition-metal-catalyzed sp3 C-H activation

All you need is an open vial! The direct α arylation of cyclic alkylamines (see scheme) requires an open vial, as the hydrogen atom involved in the C(sp3)-H-activation process is ultimately released as hydrogen gas. Reports on the formation of hydrogen gas in direct transition-metal- catalyzed functionalizations are still rare. Open-vial reactions proved crucial to this direct arylation procedure as, upon sealing, catalyst deactivation occurs.

2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

THIAZOLE DERIVATIVES AND USE THEREOF

The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.